Prospective randomized comparison of effect on coronary endothelial and renal function between febuxostat and benzbromarone in hyperuricemic patients with coronary artery disease: EFEF study.
coronary artery disease
endothelial function
febuxostat
renal function
uric acid
Journal
Health science reports
ISSN: 2398-8835
Titre abrégé: Health Sci Rep
Pays: United States
ID NLM: 101728855
Informations de publication
Date de publication:
Mar 2022
Mar 2022
Historique:
received:
23
08
2021
revised:
01
02
2022
accepted:
06
02
2022
entrez:
31
3
2022
pubmed:
1
4
2022
medline:
1
4
2022
Statut:
epublish
Résumé
There are two types of serum uric acid-lowering agents, the xanthine oxidoreductase (XO) inhibitor and non-XO inhibitor. We investigated whether febuxostat, XO inhibitor, could produce more favorable effects on coronary endothelial function (CEF) and renal function than benzbromarone, non-XO inhibitor, in hyperuricemic coronary artery disease (CAD) patients. We divided 21 hyperuricemic patients with stenting for left anterior descending (LAD) or left circumflex (LCX) artery into patients started on febuxostat (F group) and those on benzbromarone (B group). After 8 months, all patients underwent CEF evaluations (acetylcholine provocation test) and optical coherence tomography (OCT) for non-culprit vessels (e.g. if patients received LAD stenting, we evaluated LCX). We compared the diameter ratio induced by acetylcholine and baseline (CEF ratio), thin-cap fibroatheroma and calcified plaque by OCT, uric acid, oxidative stress biomarkers, and renal function including estimated glomerular filtration rate (eGFR) between F and B groups. Creatinine 2 days after stenting was measured to evaluate contrast-induced nephropathy (CIN). Change of eGFR was significantly lower in F group ( In conclusion, 8-months of febuxostat, XO inhibitor, does not significantly protect CEF but can protect the renal function including CIN in hyperuricemic patients with CAD compared to benzbromarone, non-XO inhibitor.
Sections du résumé
Background and Aims
UNASSIGNED
There are two types of serum uric acid-lowering agents, the xanthine oxidoreductase (XO) inhibitor and non-XO inhibitor. We investigated whether febuxostat, XO inhibitor, could produce more favorable effects on coronary endothelial function (CEF) and renal function than benzbromarone, non-XO inhibitor, in hyperuricemic coronary artery disease (CAD) patients.
Methods
UNASSIGNED
We divided 21 hyperuricemic patients with stenting for left anterior descending (LAD) or left circumflex (LCX) artery into patients started on febuxostat (F group) and those on benzbromarone (B group). After 8 months, all patients underwent CEF evaluations (acetylcholine provocation test) and optical coherence tomography (OCT) for non-culprit vessels (e.g. if patients received LAD stenting, we evaluated LCX). We compared the diameter ratio induced by acetylcholine and baseline (CEF ratio), thin-cap fibroatheroma and calcified plaque by OCT, uric acid, oxidative stress biomarkers, and renal function including estimated glomerular filtration rate (eGFR) between F and B groups. Creatinine 2 days after stenting was measured to evaluate contrast-induced nephropathy (CIN).
Results
UNASSIGNED
Change of eGFR was significantly lower in F group (
Conclusion
UNASSIGNED
In conclusion, 8-months of febuxostat, XO inhibitor, does not significantly protect CEF but can protect the renal function including CIN in hyperuricemic patients with CAD compared to benzbromarone, non-XO inhibitor.
Identifiants
pubmed: 35356803
doi: 10.1002/hsr2.563
pii: HSR2563
pmc: PMC8939499
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e563Informations de copyright
© 2022 The Authors. Health Science Reports published by Wiley Periodicals LLC.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
PLoS Med. 2020 Apr 22;17(4):e1003095
pubmed: 32320401
Angiology. 2017 Feb;68(2):132-144
pubmed: 27106252
Eur J Pharmacol. 2016 Jun 5;780:224-31
pubmed: 27038523
Heart. 2002 Mar;87(3):229-34
pubmed: 11847159
Lancet. 1992 Nov 7;340(8828):1111-5
pubmed: 1359209
Am Heart J. 2018 Mar;197:85-93
pubmed: 29447788
Clin Exp Nephrol. 2015 Dec;19(6):1044-53
pubmed: 25676011
Rev Cardiovasc Med. 2003;4 Suppl 5:S3-9
pubmed: 14668704
Eur Heart J. 2019 Jun 7;40(22):1778-1786
pubmed: 30844048
Lancet. 2010 Jun 19;375(9732):2161-7
pubmed: 20542554
Clin J Am Soc Nephrol. 2008 Jan;3(1):288-96
pubmed: 18057308
BMJ. 1999 Aug 7;319(7206):375-6
pubmed: 10435967
Cardiovasc Ther. 2018 Aug;36(4):e12432
pubmed: 29673103
Am J Cardiol. 2009 Jun 15;103(12):1657-62
pubmed: 19539072
JACC Cardiovasc Interv. 2012 Sep;5(9):966-73
pubmed: 22995884
Circ Res. 2013 Aug 16;113(5):495-504
pubmed: 23852538
Circulation. 2002 Jun 4;105(22):2619-24
pubmed: 12045167
Cardiovasc Diabetol. 2016 Jun 18;15:87
pubmed: 27317093
Heart Vessels. 2019 Jan;34(1):1-8
pubmed: 29936631
Nephrol Dial Transplant. 2014 Feb;29(2):406-13
pubmed: 24042021
Ther Clin Risk Manag. 2019 Feb 15;15:285-291
pubmed: 30858708
Int J Cardiol. 2007 Feb 7;115(2):156-8
pubmed: 16844250
Intern Med. 2016;55(22):3247-3256
pubmed: 27853065
Can J Cardiol. 2020 May;36(5):659-670
pubmed: 32389339
N Engl J Med. 2018 Mar 29;378(13):1200-1210
pubmed: 29527974
Angiology. 2017 Aug;68(7):627-632
pubmed: 27006404
Clin Ther. 2015 Jul 1;37(7):1396-401
pubmed: 25913922
J Am Coll Cardiol. 2013 Nov 5;62(19):1748-58
pubmed: 23810884
Circulation. 2001 Nov 27;104(22):2673-8
pubmed: 11723017
Circulation. 2012 Aug 7;126(6):753-67
pubmed: 22869857
Endocr Rev. 2001 Feb;22(1):36-52
pubmed: 11159815
Am J Kidney Dis. 2009 Jun;53(6):982-92
pubmed: 19339088
Sci Rep. 2016 Jan 27;6:19520
pubmed: 26814153
Circulation. 2002 Sep 24;106(13):1640-5
pubmed: 12270856
Br J Clin Pharmacol. 2000 Nov;50(5):397-404
pubmed: 11069434
Drugs. 2018 Jan;78(1):99-109
pubmed: 29139092
Heart Vessels. 2014 Mar;29(2):186-90
pubmed: 23552902
Eur J Heart Fail. 2008 Dec;10(12):1269-70
pubmed: 19008148
Clin Cardiol. 2015 Jul;38(7):430-8
pubmed: 26175183
J Am Heart Assoc. 2016 Sep 23;5(9):
pubmed: 27663415
Am J Kidney Dis. 2018 Dec;72(6):798-810
pubmed: 30177485
JAMA. 2006 Jan 11;295(2):180-9
pubmed: 16403930